Anti-TNF-α therapy is highly effective and is increasingly being used to induce remission and prevent flare-ups of IBD during pregnancy [5–7].The most commonly anti-TNF-α agents used in IBD are infliximab (IFX), adalimumab (ADA), certolizumab pegol(CZP), and golimumab. The gene discussed is TNF; the disease is inflammatory bowel disease.